6K9.F CONTEXT THERAPEUT.DL-001
- Market cap
- EUR 15.2M
- P/E
- -
- P/B
- 0.40x
- ROE
- -132.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6K9.F undervalued?
Graham numberThe Graham number of CONTEXT THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CONTEXT THERAPEUT.DL-001 fundamental analysis
No fundamental analysis for CONTEXT THERAPEUT.DL-001 yet.
CONTEXT THERAPEUT.DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CONTEXT THERAPEUT.DL-001
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The comp…
Full company profileCONTEXT THERAPEUT.DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CONTEXT THERAPEUT.DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.44M | -14.9M | -25.1M | -29.9M | -39.7M | -43.0M |
| EBITDA | - | -14.9M | -25.1M | -29.9M | -39.7M | -43.0M |
| Net Income | -10.5M | -14.8M | -24.0M | -26.7M | -36.1M | -41.2M |
| EPS | -0.65 | -0.93 | -1.50 | -0.30 | -0.39 | -0.45 |
| Balance Sheet | ||||||
| Total Assets | 51.3M | 38.0M | 16.1M | 98.1M | 68.5M | 36.5M |
| Total Liabilities | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M | 5.53M |
| Shareholders' Equity | 48.3M | 34.8M | 11.9M | 95.3M | 60.5M | 31.0M |
| Cash & Short-term Investments | 49.6M | 35.5M | 14.4M | 94.4M | 66.0M | 34.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -8.80M | -13.5M | -21.0M | -14.6M | -26.4M | -33.4M |
| Capital Expenditure | 250K | 537K | 0.00 | 14.8M | 2.03M | 8.74M |
| Free Cash Flow | -9.05M | -14.1M | -21.0M | -29.3M | -28.4M | -42.1M |
| Ratios | ||||||
| ROE | -21.7% | -42.7% | -201.9% | -28.1% | -59.7% | -132.7% |
| ROA | -20.4% | -39.1% | -149.2% | -27.2% | -52.7% | -112.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
CONTEXT THERAPEUT.DL-001 dividends
CONTEXT THERAPEUT.DL-001 has not paid dividends in the last 5 fiscal years.
Who owns CONTEXT THERAPEUT.DL-001
- Insiders 1.57%
- Institutions 72.26%
- Public & others 26.17%
- Shares outstanding 91.9M
- Free float 63.7M
CONTEXT THERAPEUT.DL-001 company profile
- Company name
- CONTEXT THERAPEUT.DL-001
- Ticker
- 6K9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- 2001 Market Street, Philadelphia, PA, United States, 19103
- Phone
- 267 225 7416
- Website
- contexttherapeutics.com
About CONTEXT THERAPEUT.DL-001
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CONTEXT THERAPEUT.DL-001 management
7- Mr. Martin A. LehrCo-Founder, President, CEO & Director · born 1984
- Ms. Jennifer Minai-AzaryCFO & Treasurer · born 1978
- Mr. Alex C. Levit Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1979
- Mr. Christopher Beck M.B.A.Senior Vice President of Operations
- Mr. Jeffrey LiebmanAssociate Director of Accounting
- Ms. Jennifer Dashnau M.B.A., Ph.D.Senior Vice President of Technical Operations
- Dr. Karen Chagin M.D.Chief Medical Officer · born 1977